Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Odyssey Group International ( (ODYY) ) has shared an update.
On October 14, 2025, Odyssey Health, Inc. entered into a Master Technology and Sub-license Agreement with NeuRX Health, Inc. for exclusive worldwide rights to BreastCheck®, a non-invasive test for breast abnormalities. This agreement, managed through its subsidiary Odyssey Medical Devices, Inc., marks a significant step in Odyssey’s portfolio, allowing them to enter the $26 billion breast cancer diagnostics market. BreastCheck® is FDA registered and provides a reliable first-line screening for breast abnormalities, complementing established procedures like mammography. Odyssey expects to begin commercialization soon, transitioning from a development-stage to a revenue-generating company.
More about Odyssey Group International
Odyssey Health, Inc. is a medical technology company focused on life-saving medical solutions. The company aims to create, acquire, and accumulate distinct assets and technologies that offer meaningful medical solutions, with a focus on areas with technological advantages and substantial market opportunities. Odyssey Medical Devices, Inc. is a wholly-owned subsidiary of Odyssey Health Inc.
Average Trading Volume: 226,480
Technical Sentiment Signal: Buy
Current Market Cap: $8.67M
For a thorough assessment of ODYY stock, go to TipRanks’ Stock Analysis page.